Forskolin

製品コードS2449 別名:Coleonol

Forskolin化学構造

分子量(MW):410.5

Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.

サイズ 価格(税別)  
JPY 23240.00
JPY 18260.00
JPY 44820.00
JPY 61420.00
JPY 94620.00

カスタマーフィードバック(2)

  • Eur J Cancer 2014 50(7), 1310-20. Forskolin purchased from Selleck.

    Measurement of cAMP accumulation in INS-1 cells. (A) INS-1, or (B) INS-1 transfected with murine GPR109A for 24 h, or (C) INS-1 transfected with human GPR109A for 24 h were incubated in DMEM (2.5 mM glucose) media with or without PTX (100 ng/ml) for 24 h. Cells were then incubated in KRB supplemented with 2.5 mM glucose, 500 μM IBMX, 10 μM forskolin, and with/without 10 or 100 μM NA for 1 h. After lysis with HCl (0.1 M), cells were sonicated and spun. The supernatants were saved for cAMP measurement by ELISA. (D) Reduction of cAMP accumulation in INS-1 and INS-1 cells transfected with GPR109A in the presence of 10 or 100 μM NA. White bar: INS-1 cells, grey bar: INS-1 cells transfected with murine GPR109A; black bar: INS-1 cells transfected with human GPR109A. (∗ and #p < 0.05, ∗ and ##p < 0.001). (n = 5).

    Gen Comp Endocrinol, 2016, 237:98-108. Forskolin purchased from Selleck.

製品安全説明書

cAMP阻害剤の選択性比較

生物活性

製品説明 Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.
ターゲット
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
体外試験

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 NYjuT4RYTnWwY4Tpc44hSXO|YYm= MoDENVAh|ryP M4XFSlYhcA>? NEnsXYxqdmO{ZXHz[ZMheGixc4Doc5J6dGG2aX;uJI9nKG:4ZYLlfJBz\XO|ZXSgT2xJVDNiYYSgV|Q{Ow>? NITvToUzPjR|NUS5PC=>
Mo-DCs M3XVW2Z2dmO2aX;uJGF{e2G7 NHTIO3Y2OCEQvF2= NVLLVI1vOjUkgJno NYHkcFdXeHKxbX;0[ZMhUUxvMkOgdJJw\HWldHnvckBqdiC2aHWgd5Vx\XKwYYThcpQhd2Zieontc5NidiC|dHnteYxifGWmIF3vMWREe8Li MmS0NlY1OTJ7NEi=
RBMECs  MUTGeY5kfGmxbjDBd5NigQ>? M3nwVVXDqM7:TR?= M3OzNFHDqGh? M1voSoJtd2OtczD0bIUhWmGlMTDpcoFkfGm4YYTpc44hcW6mdXPl[EBjgSCHTVHQMWlK MYiyOlM2QDB|OR?=
INA-6 NH;SVlZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NUTGXVhHOC1zMECg{txO MWG3NwKBkWh? M1XPU4lv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 M1L0TVI3OzB4NkK0
OPM-2 MX7D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUf5U5lOOC1zMECg{txO NEG5UnM4OuLCiXi= MUjpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= MViyOlMxPjZ{NB?=
U266 NH;HW2JE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NInzbVUxNTFyMDFOwG0> NWPsNmo6PzMkgJno Mmj4bY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= NGjqSY4zPjNyNk[yOC=>
H929 MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnPPNE0yODBizszN NVHKW4NDPzMkgJno MnjLbY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= NEXG[5MzPjNyNk[yOC=>
RPMI 8226 M2XYbGNmdGxiVnnhZoltcXS7IFHzd4F6 NV7zUXRzOC1zMECg{txO MXm3NwKBkWh? NFjWUmFqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> NXjB[nZCOjZ|ME[2NlQ>
MDCK  M2XOdmZ2dmO2aX;uJGF{e2G7 M{Pi[FExKML3TR?= MnfMNlQhcA>? Mm\xSG1UVw>? M{jOWZVxemWpdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKFSJRj5OtlEh[W6mIFPUS2bDqA>? NUP3PGRTOjZ{MEKzOVI>
MDCK  NHqxdYVHfW6ldHnvckBCe3OjeR?= MYWxNEDDvU1? NFHPbGUzPCCq MmjLSG1UVw>? MXnpcohq[mm2czD0bIUhcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gSm4h[2G3c3XkJIJ6KFSJRj5OtlE> M{j5Z|I3OjB{M{Wy
Spinal cords  MnTjSpVv[3Srb36gRZN{[Xl? NEfoeZUyyqEQvF2= M33JbFMxKG2rbh?= MVHzeIlufWyjdHXzJINCVVBibHX2[Yx{ M2\YNlI3OTJ4OUK2
BeWo  MV;GeY5kfGmxbjDBd5NigQ>? Ml2wNlXjiIoQvF2= MkWwNlQwPDhxN{KgbC=> M3L5b4xm[WS|IITvJIFvKGmwY4LlZZNmKGmwIITo[UBmgHC{ZYPzbY9vKG:oIH;0bIVzKG[3c3nvckBu[XKtZYLz NU\sPWNFOjZyNUO1OFk>
bovine oocytes NV\MPZFMTnWwY4Tpc44hSXO|YYm= NFu3UFAyODEEoN88US=> MX:xNuKhcA>? M2n3cIlvcGmkaYTzJJRp\SCnZn\lZ5Qhd2ZiTmDQRUBidmRxb4KgUnBRSyC2bzDzeIlufWyjdHWgdoV{fW2ydHnvckBw\iCvZXnvd4l{ MlvCNlYxPTF4MUG=
Caco-2  M125N2Z2dmO2aX;uJGF{e2G7 MojMNE4yNzFxMUCg{txO NWPiO2VzOjEEoH3pci=> MWHpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gbY51emGlZXzseYxieiClQV3QJIxmfmWucx?= M{DT[FI3ODR7MUCy
Caco-2  Mn72SpVv[3Srb36gRZN{[Xl? MnSwNE4yNzFxMUCg{txO NYHVW|ZIOjRiaB?= MWPpcoNz\WG|ZYOgUXJROiCycn;0[YlvKGyndnXs M2\BTlI3ODR7MUCy
AML-12  M1Wy[GZ2dmO2aX;uJGF{e2G7 M1zEe|IxKM7:TR?= M1\YWFMhcA>? NIf2cHp2eHKnZ4XsZZRmeyC2aHWgdIhwe3Cqb4L5cIF1cW:wIHzleoVteyCjdDDUbJIuPDFzIHHu[EBU\XJvNEmz MV:yOlA1QDl6NR?=
AML-12  M3G5OmZ2dmO2aX;uJGF{e2G7 MVOyNEDPxE1? M{LXRlEuQCCq M3LSU4lv[3KnYYPld{BodHWlb4PlJJBzd2S3Y4Tpc44> MVOyOlA1QDl6NR?=
AML-12  NUXTboRCTnWwY4Tpc44hSXO|YYm= NEXuRowzOCEQvF2= M4DYT|MhcA>? NIe3dVd2eC2{ZXf1cIF1\XQEoGDnZ|FiNMLiUHXwZ4stKGGwZNMgS|Zx[8LibWLORUBt\X[nbIO= M3HEblI3ODR6OUi1
AML-12  M{jTPWZ2dmO2aX;uJGF{e2G7 NF;NR2EzOCEQvF2= M{Hq[FMhcA>? MX3pcoR2[2W|IITo[UBl\XCqb4PwbI9zgWyjdHnvckBw\iCFUmTDNuKh NEm3XnQzPjB2OEm4OS=>
RBMECs MmHXSpVv[3Srb36gRZN{[Xl? NVLWWlN7PcLizszN Mo[3NUBp M3jrVYlvcGmkaYTzJGVOSVBvSVmtbY5lfWOnZDDpcoFkfGm4YYTpc44hd2ZiUnHwNeKh MUWyOlA1PDZ4Mx?=
EndoC-βH1 Mk[3SpVv[3Srb36gRZN{[Xl? NYHLU4hoPcLizszN M3XMVlEhcA>? MVXwc5RmdnSrYYTld{BodHWlb4PlMYlv\HWlZXSgbY5{fWyrbjDz[YNz\XSrb36gbY4hfGinIIDy[ZNmdmOnIH;mJIdtfWOxc3W= M1nGTFI3ODJ6NU[y
EndoC-βH1 NUXPPXQyTnWwY4Tpc44hSXO|YYm= MUG1xsDPxE1? Ml3PNUBp M3HRU4xm[WS|IITvJIEhe3S{b37nJINCVVBiaX7jdoVie2V? MXeyOlAzQDV4Mh?=
SH-SY5Y NEC5cXVHfW6ldHnvckBCe3OjeR?= M2\KRlMxKM7:TR?= MYWzNEBucW5? NYXmTXV{TE2VTx?= MUHzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgZYN1cX[jdHnvckBw\iCSS1G= MWWyOlAzPTF|Nx?=
PC-3 M1;nSmZ2dmO2aX;uJGF{e2G7 M{D1U|QxKML3TR?= MV2yJIg> M1raVWROW09? M2fLVIxm[WS|IITvJHBROkFiYXP0bZZifGmxbh?= Mk\XNlYxOjN6M{[=
PC-3 NF3GTXZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFvvUmU1OCEEtV2= MnK0NlQwPDhxN{KgbC=> M1rwTmROW09? MlTt[IVkemWjc3XzJINmdGxidnnhZoltcXS7IITpcYUh\GWyZX7k[Y51dHl? NUDiRXVmOjZyMkO4N|Y>
SCG NV;DOIhoTnWwY4Tpc44hSXO|YYm= NGXRemszOCEQvF5CpC=> MkfESG1UVw>? MnvudoV3\XK|aXLsfUB{fXCycnXzd4V{KEmNVjD3bZRpKGFiSVO1NEBw\iB{ND60JO69VQ>? MUGyOVk3OjF|Mh?=
HEK-293 MlT0SpVv[3Srb36gRZN{[Xl? NFH2WIg{PSEQvF5CpC=> MUPEUXNQ MV\pcoR2[2W|IHGgZ49ve3CrY4XveZMh6oDeaX7hZ5RqfmG2aX;u5qCeKG:oIITo[UBMfjJwMTDjeZJz\W62 M2n1cVI2QTZ{MUOy
SCG M2n0fWZ2dmO2aX;uJGF{e2G7 NHPxToMyODBizszNxsA> NU\LUIM4TE2VTx?= M2HBWJJm\HWlZYOgeIhmKGW6Y3n0ZYJqdGm2eTDv[kBUS0dibnX1do9vew>? MXSyOVk3OjF|Mh?=
PCCL3 NEDvOZdHfW6ldHnvckBCe3OjeR?= MoLENVAhyrWP NEDDdHczPCCq MUnlcohidmOnczDEeW95OiCycn;tc5RmeiC2cnHud4NzcXC2aX;uJIFkfGm4aYT5xsDjiIt? NYrSTo9zOjV7NkC5OVY>
3T3-L1 preadipocytes M3;QfGZ2dmO2aX;uJGF{e2G7 MknENVAh|ryPwrC= NH;BVo0yOiCq NVnEeZZRcW6mdXPld{BEWkWEIIDoc5NxcG:{eXzheIlwdiCjbnSgR{9GSlEQsjDlfJBz\XO|aX;u Mn3PNlU6OjhyNUi=
H295R  NXPjT2RETnWwY4Tpc44hSXO|YYm= MXexNOKh|ryP M1zNXlQ5yqCq M2POXIlv[3KnYYPld{B{fGW{b3nkJI1mfGGkb3zpeIV{KGmwIITo[UBidmS{b3flckwhdWmwZYLhcI8uKGGwZDDncJVkd2OxcoTpZ49q\CCyYYToe4F6ew>? NV3Y[VE6OjV6Nkm1OVY>
PBMC M1PCW2Z2dmO2aX;uJGF{e2G7 M2L1TFUxyqEQvF2= NUPKUZlNOjUEoHlCpC=> MWfpcohq[mm2czD0bIUhcW6lcnXhd4VlKHOnY4LleIlwdiCxZjDUUmYhcW6mdXPl[EBjgSC2aHWgSHBG MoDzNlU5PjZyN{m=
GLUTag  M{PWNmZ2dmO2aX;uJGF{e2G7 M37iUlEx6oDLwsXN MXqwM|IwPCCq M3TOWZN1cW23bHH0[ZMhT0ySLUGgd4VkemW2aX;uJINwfHKnYYTl[EB4cXSqIFnCUXg> NVPjb2c6OjV6M{K2N|E>
GLUTag  Mn;WSpVv[3Srb36gRZN{[Xl? MlziNVDjiIoEtV2= NEHndWQ1KGh? NWrpPJpicW6lcnXhd4V{KHSqZTDwR3JGSiCuZY\lcJMhf2m2aDD0bIUhUUKPWB?= NYSyWol6OjV6M{K2N|E>
BAECs MVTGeY5kfGmxbjDBd5NigQ>? M3jQWVI2KM7:TR?= MUSyOEBp NInRWohmdmijbnPld{B1cGViYXP0bZZifGmxbjDv[kBRWEGUzsGgZpkhPSEQvF2gdoV{fmW{YYTyc4wtKFR2SGOsJI9zKDRvUFHQ NUGxb4pDOjV5OUi4NlY>
PC12 MWrGeY5kfGmxbjDBd5NigQ>? MWSyOeKh|ryP MoC2OFghcA>? M37aboFkfGm4YYTld{BkSU2S M3O3bFI2PzZ7M{C1
GH3 MoG5SpVv[3Srb36gRZN{[Xl? MWmxxsDPxE1? MXS2MYg> NXvyXHlM[XS2ZX71ZZRmeyC2aHWgZ49zemWuYYTpc44h[mW2d3XlckBRWkxiYX7kJGJu[WxzIHX4dJJme3Orb36= NWD6[3ZIOjV5MkewNVg>
GH3 MkXWSpVv[3Srb36gRZN{[Xl? NX3reoZqOcLizszN NHniblY3NWh? MXrpcoR2[2W|IGDSUEBidmRiQn3hcFEtKGK3dDDuc5QhS2yxY3usJI1TVkFiZYjwdoV{e2mxbh?= M{X0OlI2PzJ5MEG4
BeWo NGrQOItHfW6ldHnvckBCe3OjeR?= MWqxNQKBks7:TdMg Mn[xO|IhcA>? MkjqSG1UVw>? MlTucYVlcWG2ZYOgRoVYdyClZXzsJIRq\m[ncnXueIlifGmxbh?= M{jw[FI2PzF|NEK1
oocytes MYPGeY5kfGmxbjDBd5NigQ>? NHjSWGg2KM7:TR?= M2LKSlI1KGh? NFqyN3hifHSnboXheIV{KHKqLXnud5VtcW5iYXP0bY9vKG:wIH;vZ5l1\SCJVlLEJJNq\26rZnnjZY51dHoEoB?= MVqyOVcxPzh3NB?=
SC MXnGeY5kfGmxbjDBd5NigQ>? MkfENE42KM7:TR?= MViyOEBp MYjtbY1q[2u|IITo[UBm\m[nY4Sgc4Yh[0GPUDDhcoFtd2e|IH;uJG8yKGGwZDDNRnAh\XiycnXzd4lwdg>? M2HRb|I2PzB3OEe0
SC MnjpSpVv[3Srb36gRZN{[Xl? M3fuWVAvPSEQvF2= MonMO|IhcA>? MUHpcoNz\WG|ZYOgZo91cCCNcn;4MVIxKGGwZDDPNUBmgHC{ZYPzbY9vKGmwIHH4c44uemWuYYTl[EBUS3NiYoX0JI9vdHliS4LvfE0zOMLi MXKyOVcxPTh5NB?=
UACC-647  MVzGeY5kfGmxbjDBd5NigQ>? Mn3pSG1UVw>? M4rHUYxm[WS|IITvJIEhemm|ZTDpckBkSU2SIHzleoVteyBqRVO1NOKhRcLiMkCuN|nDqM7:TTm= M4fmWVI2PzB|MEK1
UACC-647  M3fnU2Z2dmO2aX;uJGF{e2G7 MWexNOKh|ryP MWGxOUBucW5? NULJXXlxTE2VTx?= Mn72bY5pcWKrdIOgSXJMKHCqb4PwbI9zgWyjdHnvci=> M3;USVI2PzB|MEK1
UACC-647  NYTrWFBNTnWwY4Tpc44hSXO|YYm= M3jNNVExyqEQvF2= MUKxOUBucW5? MYHEUXNQ MmTRbY5kemWjc3XzJIVGTjJicHjvd5Bpd3K7bHH0bY9vKGyndnXsd:Kh NX\UcnpYOjV5MEOwNlU>
SH-SY5Y  MWDGeY5kfGmxbjDBd5NigQ>? MV:xNOKh|ryP NX7WfXZkOcLiaNMg MmLNbY5kemWjc3XzJGxWSyCjY4Tpeol1gQ>? NYDoTFJbOjV3OUe0N|M>
SH-SY5Y  MVvGeY5kfGmxbjDBd5NigQ>? M1f0fVExyqEQvF2= MWSxxsBpyqB? Mli1bY5kemWjc3XzJGFISzFibWLORUBt\X[nbB?= MViyOVU6PzR|Mx?=
hADSCs MnfCSpVv[3Srb36gRZN{[Xl? MoHPOgKBkcL3TR?= M3vOW|MxKG2rbh?= NYjNTY5rcW6lcnXhd4V{KGODTWCgcIV3\Wy| NIXKXXUzPTV7MUmwPC=>
HEK293  Mn3rSpVv[3Srb36gRZN{[Xl? Mly0OgKBkcL3TR?= NX3nNlNyOzBibXnu M2H6Wolv[3KnYYPld{BkSU2SIHzleoVtew>? NEe1SYYzPTV7MUmwPC=>
3T3-L1 MULGeY5kfGmxbjDBd5NigQ>? NWrxcYlKOi53L{Wg{txO NITleW4zPCCqwrC= M4m5cpNq\26rZnnjZY51dHliZHXjdoVie2W|IFHUS2wheHKxdHXpckBmgHC{ZYPzbY9vKGG2IHHscEBld3OnczD0[ZN1\WR? M1jHfVI2PTlyNUm3
OCI-Ly1  NXjPXGcxTnWwY4Tpc44hSXO|YYm= Mlu4OFDDqM7:TR?= MXuxxsBpyqB? NFXOe2FFVVOR MVrpcoR2[2W|IITo[UBqdmO{ZX3lcpQhd2ZiY1HNVEBkd26lZX70doF1cW:wcx?= M1rYblI2PTd4MkKw
OCI-Ly18  MmfZSpVv[3Srb36gRZN{[Xl? MmL4OFDDqM7:TR?= MV[xxsBpyqB? NITnPHVFVVOR NVHscYtZcW6mdXPld{B1cGViaX7jdoVu\W62IH;mJINCVVBiY3;uZ4VvfHKjdHnvcpM> MUCyOVU4PjJ{MB?=
BeWo M4j4WGZ2dmO2aX;uJGF{e2G7 MUWyNOKhyrWP NH[0clA1QMLiaB?= M3jQd2ROW09? NVPEe216cW6lcnXhd4V{KHSqZTDkbYZn\XKnboTpZZRqd25ib3[gRoVYdyClZXzsdy=> NU\We5ZQOjV3Nk[3OFA>
BeWo MXHGeY5kfGmxbjDBd5NigQ>? MojpNlDDqML3TR?= NGXHc3U1QMLiaB?= M13LWWROW09? NV7PRXFQcW6lcnXhd4V{KHSqZTDh[Ihme2mxbjDv[kBVUFBvMTDtc45w[3m2ZYO= MYGyOVU3Pjd2MB?=
LNCaP  MWXGeY5kfGmxbjDBd5NigQ>? NIDKTWgyOMLizszN MX2xNkBpyqB? NYT4RoFPTE2VTx?= NUPMbFBYcW6mdXPld{BiKGS{YX3heIlkKGmwY4LlZZNmKG:oIFPSSWIyKGGldHn2bZR6 M4\URVI2PTR6MEm5
ThGCs  NYHRO4dpTnWwY4Tpc44hSXO|YYm= NGTufIEyOOLCit88US=> MWW05qCLcA>? MVjheYdu\W62czDITWYySSCuZY\lcJMhfGijdDD3[ZJmKHO2aX31cIF1\WRiYomgR49EdDJ? Mki1NlU1OzNyMke=
ThGCs  M4TKZWZ2dmO2aX;uJGF{e2G7 MlT4NVDjiIsQvF2= NEPvOII16oDMaB?= M1;WS4lv[3KnYYPld{BEd0OuMj3pcoR2[2WmIFXEUlLDqGenbnWg[ZhxemW|c3nvci=> NXv5dW1rOjV2M{OwNlc>
ThGCs  M3[5OGZ2dmO2aX;uJGF{e2G7 NFXuN|MyOOLCit88US=> M3\xWVMhcA>? MYDpcohq[mm2czD0bIUh\W[oZXP0JI9nKEh{T{Kgc44hTUSQMjDtVm5C NUfiSmwyOjV2M{OwNlc>
RBMECs NHzNb|ZHfW6ldHnvckBCe3OjeR?= MYOwMlA2NzBwNT:1JO69VQ>? MWiwMlI2KGh? NELIbXFqdmO{ZXHz[ZMh[0GPUDDjc45k\W62cnH0bY9v M1rnU|I2PDF4NkWx
RBMECs MnHwSpVv[3Srb36gRZN{[Xl? MkDUOeKh|ryP NVz3fY9HOSCq NXHGNWlM[myxY3vzJJRp\SCjY4TpeoF1cW:wIH;mJHJpd0FxUl;DT{BqdmS3Y3XkJIJ6KEWPQWCtTWk> NV\wbo41OjV2MU[2OVE>
RBMECs MX3GeY5kfGmxbjDBd5NigQ>? MojFOeKh|ryP MmC4NUBp NWLnd5c3eHKndnXueJMhfGinIFXNRXAuUUlvaX7keYNm\CCWRVXSJJZidHWnIHTlZ5Jm[XOn NEjVVIozPTRzNk[1NS=>
RBMECs MVPGeY5kfGmxbjDBd5NigQ>? MVW1xsDPxE1? MorxNUBp NE\qXWRxemW4ZX70d{B1cGViaX7jdoVie2ViaX6gTHJRKG[udYigZYNzd3O|IITo[UBDXEJiaX7keYNm\CCkeTCgSW1CWC2LSR?= NFvySFczPTRzNk[1NS=>
RBMECs MljlSpVv[3Srb36gRZN{[Xl? NUe0VoQ1PcLizszN M{\vdVEhcA>? M1;5XIlvcGmkaYTzJJRp\SCmZXPy[YF{\WRib3[gZY1wfW62IH;mJHpQNTFiaX6gUWZ{KGmwZIXj[YQh[nliRV3BVE1KUQ>? MWiyOVQyPjZ3MR?=
RBMECs NWDvS2tITnWwY4Tpc44hSXO|YYm= NVHPfFd1PcLizszN M{DYV|EhcA>? NEfJOWFz\X[ncoPld{B1cGViY3jhcodmeyCrbjDaU{0yKGSrc4TybYJ2fGmxbjDz[YVvKHerdHigSW1CWC2LSTD0doVifG2nboS= NIr2RZAzPTRzNk[1NS=>
RBMECs M4LZ[GZ2dmO2aX;uJGF{e2G7 NW\qXYMxPcLizszN NV;OXXZqOSCq NGXaeHljdG:la4OgeIhmKEWPQWCtTWkucW6mdXPl[EBkcGGwZ3WgbY4hVUyFIIDoc5NxcG:{eXzheIlwdg>? NF71cXozPTRzNk[1NS=>
RBMECs MkTYSpVv[3Srb36gRZN{[Xl? NYPS[4dTPcLizszN NX2wVnhmOSCq NELoXZZjdG:la4OgeIhmKGGldHnuJIN6fG:|a3Xs[ZRwdiC{ZXHydoFv\2WvZX70JJNm\W5id3n0bEBGVUGSLVnJJJRz\WG2bXXueOKh MXSyOVQyPjZ3MR?=
Primary bovine chondrocytes MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf2UGtGPc7:TR?= NWTLSJhOPDhiaB?= NVLOcZJzemW4ZYLz[ZMhfGinIHnubIljcXSxcomg[YZn\WO2IH;mJINmdGWlb4jpZkBwdiCycn;sbYZmemG2aX;uJIlvKGe{b4f0bEBxdGG2ZTDjbI9v\HKxY4n0[ZM> MnnWNlU1ODZyMU[=
EM1  NFLsPFZHfW6ldHnvckBCe3OjeR?= NX\KOWd3OTYkgJtOwG0> MYS0PEBp MlfYdoVlfWOnczD0bIUh\XiycnXzd4lwdiCxZtMgUGlHyqCxctMgVHRIWzMEoHnuxsBESUyULTDvduKhTVCDQ{Ktd4lt\W6lZXSgSW0yKGOnbHzzxsA> MlPTNlU{Pzh4NkG=
BeWo  NYDNc25HTnWwY4Tpc44hSXO|YYm= Mm\yNlDDqML3TR?= MWO0POKhcMLi NUjPcpk3TE2VT9Mg NInVdnJqdmO{ZXHz[ZMhfGinIHLleIEucEOJIILlcIVie2V? NEH0UFMzPTN4MkK2NC=>
BeWo  M1TxNmZ2dmO2aX;uJGF{e2G7 Mn;ZNlDDqML3TR?= NXHRN5lWPDkEoHlCpC=> Mmr2SG1UV8Li MX7kc5dvemWpdXzheIV{KHSqZTDs[ZZmdCCxZjDUUWVOTjF4 MkLMNlU{PjJ{NkC=
BeWo  NYjFNVltTnWwY4Tpc44hSXO|YYm= MlnFNlDDqML3TR?= NHmxe4s1QMLiaNMg NXnGZlJ7TE2VT9Mg NUDVS4pk\G:5boLl[5Vt[XSnczD0bIUhdGW4ZXygc4YhT0OPLUG= MlfhNlU{PjJ{NkC=
granulosa cells NHHUPYRHfW6ldHnvckBCe3OjeR?= Mlq5NVAh|ryP MonUNVIwOjRiaB?= MmrvbY5kemWjc3XzJJRp\SCuZY\lcJMhd2cEoGLHV|LDqG2UTlG= NI\FWHozPTN|OUGwOS=>
granulosa cells MYDGeY5kfGmxbjDBd5NigQ>? NWrWPYVCOTBizszN MX:xNk8zPCCq MXjpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC{ZYDvdpRmeiCjY4Tpeol1gSCob4KgeIhmKGyxbnfld5Qh\nKjZ33lcpQhMOLKkki1OE8sOTiUR2OyMmxWSyl? NVP1TZdKOjV|M{mxNFU>
granulosa cells MX3GeY5kfGmxbjDBd5NigQ>? NF7ZPGEyOCEQvF2= M365[|I1KGh? NEfWb|VqdmO{ZXHz[ZMhfGinIHnueIVve2m2eTDv[kBFVkFxcILveIVqdiClb33wcIV5 M125U|I2OzN7MUC1
granulosa cells MYTGeY5kfGmxbjDBd5NigQ>? NHXXSYEyOCEQvF2= MXuyOEBp NW\FNHpOcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gVmdUOiCycn;tc5RmeiCjY4Tpeol1gQ>? MX2yOVM{QTFyNR?=
SK-N-AS  MWLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MU[xNEDPxE4EoB?= MnvQNlQwPDhiaB?= MWjlcohidmOnczD0bY1mNWSncHXu[IVvfGy7IHPlcIx2dGG{II\pZYJqdGm2edMg MXuyOVI3PjB4Mx?=
SK-N-AS  MmK0SpVv[3Srb36gRZN{[Xl? NHvFbmMyOCEQvF5CpC=> MYiyOEBp MXvpcoNz\WG|ZYOgeIhmKGODTWCgcIV3\Wy|wrC= NUXDWmpMOjV{Nk[wOlM>
SK-N-AS  M2r3PGZ2dmO2aX;uJGF{e2G7 Mn\QNVAh|ryPwrC= NGO5PYMzPCCq NYHYb2FucW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGO7Y3zpckBFOQ>? MX6yOVI3PjB4Mx?=
SK-N-AS  M4TjV2Z2dmO2aX;uJGF{e2G7 NUOxNXVCOTBizszNxsA> NULRSoVKOzBibXnu MWjpcoR2[2W|IIDoc5NxcG:{eXzheIlwdiCxZjFOtk1k[XSnbnnuJEh{\XJ4N{WpMEBxNUeVS{ROtkApe2W{OTmgZY5lKGOxbnPvcYl1[W62IHjp[4hmeiCuZY\lcJMhd2ZiYXP0bZZmNCC3boDoc5NxcG:{eXzheIVlNCEQsj3jZZRmdmmw MkTaNlUzPjZyNkO=
SK-N-AS  MYfGeY5kfGmxbjDBd5NigQ>? NH[4coEyOCEQvF5CpC=> NX;uPY9IOTBxM{CvOlAhdWmw NV:3ZYhGcW6lcnXhd4V{KGyndnXsd{Bw\iCyLd8yMYNifGWwaX6gLJNmejZ5NTmgZY5lKGmwZIXj[ZMh[WOldX31cIF1cW:wIH;mJJAu|rJvY3H0[Y5qdiBqc3XyOlc2MSCrbjCodIVzcSmwdXPs[YFzKHKnZ3nvcpM> MkLYNlUzPjZyNkO=
SK-N-SH Mo\UR4VtdCCYaXHibYxqfHliQYPzZZk> MYKxNEDPxE4EoB?= MonmOFghcA>? NIm4T5ZmdmijbnPld{BUUy2QLWPIJI5mfXKxYnzhd5RwdWFiY3XscEB3cWGkaXzpeJk> Ml\uNlUzPjZyNkO=
HEK‐CFTR MnnKSpVv[3Srb36gRZN{[Xl? MXyy5qCUPTEEoN88US=> NV7MXmxEOC1zMjDtbY4> NUDDUZlkTE2VT9Mg MXrpcoR2[2W|IHGg[I9{\eLCkHTldIVv\GWwdDDpc4Rq\GViZX\mcJV5yqB? NYfMboZJOjV{NkOyNFc>
L6 M1nue2Z2dmO2aX;uJGF{e2G7 MX[0NEDDvU1? M3fZS|I1KGh? NHe2[GJqdmirYnn0d{BFVUhzLXnu[JVk\WRiQXv0JIFkfGm4YYTpc44> MkWxNlUzPDd3NUC=
MIN6  M37EcWZ2dmO2aX;uJGF{e2G7 NWjoZ5N4OTBizszNxsA> Ml34N{Bp NW\xZXpOcW6lcnXhd4V{KER|IH3SUmEh\XiycnXzd4lwdg>? M2Hyb|I2OjRzMUK0
ventricular cardiomyocytes  MYDGeY5kfGmxbjDBd5NigQ>? M1fiXFAvODFvMUCg{txO MULpcoNz\WG|ZYOgJINCVVBiYXPjeY12dGG2aX;u M3HOSFI2OjB|MUGz
ventricular cardiomyocytes  NWHpZnBMTnWwY4Tpc44hSXO|YYm= NUnZWYdwOC5yMT2xNEDPxE1? NFP4[oFmfm:tZYOgZY4hcW6xdILvdIlkKHKnc4DvcpNmKDF{MNMxNVUmKGGkb4\lJIJie2GuIIfpeIgh[W5iRVO1NOKhd2ZiMj6yJOK2VQ>? NGHZV4MzPTJyM{GxNy=>
BeWo  MX7GeY5kfGmxbjDBd5NigQ>? NUfHT4NROjBiwsXN M{PLRVQ5KGh? MnWySG1UV8Li MkL2bY5lfWOnczDj[YxtKG[3c3nvci=> MkXNNlUyQDR2N{e=
THP-1  MoXLSpVv[3Srb36gRZN{[Xl? NIDVRlMyNzFyIN88US=> M{S5cVLDqGh? NH[2SZFFVVORwrC= M4S2VJN2eHC{ZYPz[ZMhVUOSLUGgdJJw\HWldHnvcuKh MV[yOVE2PDh6Mh?=
Huh-7 NH\yR2hHfW6ldHnvckBCe3OjeR?= NFXMS40xNTJyIN88US=> Mn3INkBpyqB? NUXOcGlRemW|dXz0d{BqdiCjIHTvd4Uu\GWyZX7k[Y51KGmwY4LlZZNmKGmwIHOtUZlkKGW6cILld5Nqd25iYYSgeIhmKHC{b4TlbY4h[W6mIH3SUmEhdGW4ZXzz NY[zNXNmOjVzMEm4N|Q>
C6 NFnFfFlHfW6ldHnvckBCe3OjeR?= MXyxNEDPxE4EoB?= MoLsNlAhdWmw NYnKdWdTcW6lcnXhd4V{KGODTWCgZYNkfW23bHH0bY9v MnezNlUxPjl2MUe=
SW480 NGGxRYhHfW6ldHnvckBCe3OjeR?= M1\PcFQxyqEQvF2= NHHHNIg1QMLiaB?= NEnLVIJFVVOR NEPEe4li[3SrdnH0[ZMhWFB{QR?= NFfTfJczPDl7N{S1NS=>
HT-29  NVTFTYJ7TnWwY4Tpc44hSXO|YYm= MnmzOFDDqM7:TR?= M1f3TlQ5yqCq MnfJSG1UVw>? M4X5WIFkfGm4YYTld{BRWDKD Mk\RNlQ6QTd2NUG=
SW480 NHzhd3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILv[JM1OMLizszN NIXCPZYxNTd{IHi= Mn2ySG1UVw>? NWPtbnZmcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? MVSyOFk6PzR3MR?=
HT-29  NHHvWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHuyT3A1OMLizszN MmXpNE04OiCq NGXQOoFFVVOR MWjpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 M2H5S|I1QTl5NEWx
SW480 MXnGeY5kfGmxbjDBd5NigQ>? M4jPSVQxyqEQvF2= M1SzSVch\A>? NFXn[HVFVVOR MYny[YR2[2W|IHPvcI9vd3OyaHXy[UBnd3KvYYTpc44h[2GyYXLpcIl1gcLi MmPCNlQ6QTd2NUG=
HT-29  NYDWfWk5TnWwY4Tpc44hSXO|YYm= NGftdFA1OMLizszN MWe3JIQ> NHPQeVhFVVOR NVLuOWRPemWmdXPld{Bkd2yxbn;zdIhmemViZn;ycYF1cW:wIHPhdIFjcWyrdIpCpC=> M33vSFI1QTl5NEWx
SW480 M3;2VGFxd3C2b4Ppd{BCe3OjeR?= Mnq4OFDDqM7:TR?= M2LldFQ5yqCq M3\ZZWROW09? MYnpcoR2[2W|IHHuJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|L{e= NHnndI0zPDl7N{S1NS=>
HT-29  M2n5U2Fxd3C2b4Ppd{BCe3OjeR?= MXq0NOKh|ryP MYS0POKhcA>? NVy3T|FpTE2VTx?= NV;FV3BpcW6mdXPld{BidiCjY4TpeoF1cW:wIH;mJINie3Cjc3WgN{84 NEDjOFMzPDl7N{S1NS=>
SW480 NXLOd2hRSXCxcITvd4l{KEG|c3H5 M1n0fFQxyqEQvF2= MWK0POKhcA>? M1m3TWROW09? NUfvPY94cW6mdXPld{BkcGGwZ3XzJIlvKHSqZTDwbI9{eGixconsZZRqd25ic4TheJV{KG:oIGDQNmEhfGG{Z3X0dy=> MV:yOFk6PzR3MR?=
HT-29  M4DFWGFxd3C2b4Ppd{BCe3OjeR?= MWi0NOKh|ryP NYLmN5htPDkEoHi= Mn;jSG1UVw>? M33iWIlv\HWlZYOgZ4hidmenczDpckB1cGVicHjvd5Bpd3K7bHH0bY9vKHO2YYT1d{Bw\iCSUELBJJRiemendIO= M2LIbFI1QTl5NEWx

多くの細胞株試験データを見る場合、クリックしてください

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.75 mM)
Ethanol 37 mg/mL (90.13 mM)
Water Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 410.5
化学式

C22H34O7

CAS No. 66575-29-9
保管
別名 Coleonol

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01254006 Completed Glaucoma University of Roma La Sapienza|vingolo enzo maria|domanico daniela|salvatore serena null --

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

cAMPシグナル伝達経路

Tags: Forskolinを買う | Forskolin ic50 | Forskolin供給者 | Forskolinを購入する | Forskolin費用 | Forskolin生産者 | オーダーForskolin | Forskolin化学構造 | Forskolin分子量 | Forskolin代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID